Cell-Based Vaccine Development Gives Protein Sciences The Chills; Challenges Include Getting Advisory Committees To Accept FDA Decisions
Executive Summary
Developing a new class of medical products takes creativity and perseverance by both sponsors and regulators, but as Protein Sciences' experience shows, bringing advisory committees up to speed on novel technologies can be just as important and challenging
You may also be interested in...
Protein Sciences To Begin Selling Novel Flu Vaccine; Flublok Has Virus-Free Appeal
The trivalent vaccine can be produced much faster than traditional vaccines and could be modified to compete with quadrivalent formulations.
Novavax, VaxInnate Receive BARDA Funds For Recombinant Flu Vaccine Development
New processes would speed vaccine production and could improve on efficacy.
Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus
Industry is questioning the fundamental statistical underpinnings of FDA's approval pathways for antibiotics even as the agency prepares to roll out several guidances to help clarify them